Gregory Cote to Osteosarcoma
This is a "connection" page, showing publications Gregory Cote has written about Osteosarcoma.
Connection Strength
1.075
-
Clinical and Molecular Analysis of Pathologic Fracture-associated Osteosarcoma: MicroRNA profile Is Different and Correlates with Prognosis. Clin Orthop Relat Res. 2019 Sep; 477(9):2114-2126.
Score: 0.161
-
An imprinted non-coding genomic cluster at 14q32 defines clinically relevant molecular subtypes in osteosarcoma across multiple independent datasets. J Hematol Oncol. 2017 05 15; 10(1):107.
Score: 0.137
-
Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells. Oncotarget. 2017 May 02; 8(18):30276-30287.
Score: 0.137
-
Androgen receptor is a potential novel prognostic marker and oncogenic target in osteosarcoma with dependence on CDK11. Sci Rep. 2017 03 06; 7:43941.
Score: 0.135
-
Evaluation of P-glycoprotein (Pgp) expression in human osteosarcoma by high-throughput tissue microarray. J Orthop Res. 2016 09; 34(9):1606-12.
Score: 0.125
-
Clinical and biological significance of PIM1 kinase in osteosarcoma. J Orthop Res. 2016 07; 34(7):1185-94.
Score: 0.124
-
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cells. BMC Cancer. 2014 Sep 19; 14:681.
Score: 0.114
-
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925. Br J Cancer. 2014 Jun 10; 110(12):2896-904.
Score: 0.111
-
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function. Br J Pharmacol. 2016 Feb; 173(3):613-26.
Score: 0.031